Koichi Minato

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Yukio Hosomi, Satoshi Morita, Shunichi Sugawara et al. · Journal of Clinical Oncology · 2019 · 483 citations

Medicine, Oncology, Pharmacology +14

Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03

Satoshi Teramukai, Toshiyuki Kitano, Yusuke Kishida et al. · European Journal of Cancer · 2009 · 342 citations · Full text

Medicine, Oncology, Cancer Immunology +11

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

Atsushi Nakamura, Akira Inoue, Satoshi Morita et al. · Journal of Clinical Oncology · 2018 · 113 citations

Medicine, Oncology, Pharmacology +8

Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L

Tetsuya Abe, Koji Takeda, Yuichiro Ohe et al. · Journal of Clinical Oncology · 2015 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

Shunichi Sugawara, Satoshi Oizumi, Koichi Minato et al. · Annals of Oncology · 2015 · 110 citations · Full text

Medicine, Oncology, Pharmacology +12